Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Open access
Bahcall, Magda, Sim, Taebo, Paweletz, Cloud P., Patel, Jyoti D., Alden, Ryan S., Kuang, Yanan, Sacher, Adrian G., Kim, Nam Doo, Lydon, Christine A., Awad, Mark M., Jaklitsch, Michael T., Sholl, Lynette M., Jänne, Pasi A., Oxnard, Geoffrey R. · 2016 · Cancer Discovery

Abstract

Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non–small cell lung cancer (NSCLC). However, the landscape of MET-specific targeting agents remains underdeveloped, and understanding of mechanisms of resistance to MET TKIs is limited. Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib. When resistance developed to this combination, a new MET kinase domain mutation, D1228V, was detected. Our in vitro findings demonstrate that METD1228V induces resistance to type I MET TKIs through impaired drug binding, while sensitivity to type II MET TKIs is maintained. Based on these findings, the patient was treated with erlotinib combined with cabozantinib, a type II MET inhibitor, and exhibited a response. Significance: With several structurally distinct MET inhibitors undergoing development for treatment of NSCLC, it is critical to identify mechanism-based therapies for drug resistance. We demonstrate that an acquired METD1228V mutation mediates resistance to type I, but not type II, MET inhibitors, having therapeutic implications for the clinical use of sequential MET inhibitors. Cancer Discov; 6(12); 1334–41. ©2016 AACR. See related commentary by Trusolino, p. 1306. This article is highlighted in the In This Issue feature, p. 1293

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-0686

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 173

Metadata

Authors
Bahcall, M., Sim, T., Paweletz, C. P., Patel, J. D., Alden, R. S., Kuang, Y., Sacher, A. G., Kim, N. D., Lydon, C. A., Awad, M. M., Jaklitsch, M. T., Sholl, L. M., Jänne, P. A., & Oxnard, G. R.
Venue
Cancer Discovery
Published
2016-12-01
Volume
6
Issue
12
Pages
1334-1341
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2526076440
Cited by
173
References
6
FWCI
15.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-16-0686
The paper
Bahcall, M., Sim, T., Paweletz, C. P., Patel, J. D., Alden, R. S., Kuang, Y., Sacher, A. G., Kim, N. D., Lydon, C. A., Awad, M. M., Jaklitsch, M. T., Sholl, L. M., Jänne, P. A., & Oxnard, G. R. (2016). Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-16-0686

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.